9. Alex Gorsky, Johnson & Johnson

Alex Gorsky
Johnson & Johnson CEO Alex Gorsky earned a pay package worth more than $20 million last year. (J&J)

9. Alex Gorsky, Johnson & Johnson
2018 pay: $20.10 million
2017 pay: $29.80 million
Change: -32%

Johnson & Johnson may have nailed its financial goals for 2018, but CEO Alex Gorsky still saw his pay drop—and not just a little.

Gorsky took a $9 million-plus pay cut for the year—going to $20.1 million from $29.8 million in 2017—with his pension value bearing the brunt of the decline. It recorded a goose egg in the increase column, down from $6.96 million the year prior.

RELATED: J&J chief Gorsky took a big pay hit in 2018 but still nabbed $20M

That wasn’t the only column that saw a decrease, though. The New Jersey drugmaker’s helmsman also saw his stock awards drop by $2 million to $10.32 million, and his options totaled $4.32 million instead of the $5.05 million they measured in 2017.

Gorsky’s base salary, on the other hand, climbed—if only a bit—after a year in which J&J exceeded both its sales and EPS growth targets and hit various other strategic goals, including bolstering the pipeline and creating value through M&A transactions. It checked in at $1.64 million, an increase of $42,308.

And other compensation, which includes personal use of J&J’s corporate aircraft, a car and driver for personal transportation, and home security-related fees, inched upward too, to $259,710 from $236,279 in 2017.

RELATED: J&J, under 'accelerating' generic and biosim attack, expects growth to bottom out in 2019

Meanwhile, Gorsky will have his work cut out for him going forward as a wave of patent expirations test the company’s top-performing pharmaceutical unit. The pharma giant will likely face a “trough” year in 2019, CFO Joe Wolk told investors on April’s first-quarter conference call, and it’ll be up to Gorsky to navigate generic and biosimilar competition to the “well-above market growth” the company expects at the end of the tunnel.

9. Alex Gorsky, Johnson & Johnson

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.